The patients with coronavirus infection usually have fever, respiratory symptoms,headache, toothache, muscle soreness, physical decline, and so on, while others areasymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitationof symptomatic patients with coronavirus infection and decrease the duration of viralshedding in both symptomatic and asymptomatic patients. This study aims to investigatethe efficacy and safety of Lianhua Qingwen capsules in patients with coronavirusinfection. The duration of viral shedding and symptoms before discharge, as well as thenegative conversion ratio and disappearance ratio of main symptoms after 7-day treatment,will be evaluated. 6-month follow-up will be performed to evaluate the effect of LianhuaQingwen on all infection events and the long-term rehabilitation of the symptoms inducedby coronavirus infection.
Not Provided
Drug: Lianhua Qingwen capsules
Lianhua Qingwen capsules: 4 capsules once, three times daily
Inclusion Criteria:
- confirmed SARS-CoV-2 Infection by virus testing;
- ≥18 years of age;
- informed consent provided.
Exclusion Criteria:
- overt bacterial infection in the respiratory tract resulting from common
pathologies, including primary immunodeficiency disease, acquired immunodeficiency
syndrome, congenital respiratory malformation, congenital heart disease,
gastroesophageal reflux disease, and abnormal lung development;
- asthma treated daily, chronic airway disease, respiratory bacterial infections
(e.g., purulent tonsillitis), acute tracheobronchitis, sinusitis, otitis media, and
further respiratory tract pathologies potentially affecting the trial's data
analysis;
- common pulmonary diseases (e.g., severe pulmonary interstitial lesions and
bronchiectasis) confirmed by chest CT;
- severe pneumonia requiring ventilator use;
- previous or present diseases potentially affecting trial participation or
influencing study outcome, based on the investigator's judgment;
- pregnancy or lactation in women;
- participation in a clinical study in the past 3 months;
- history of allergy to ≥2 drugs or foods or known allergy to the drug's constituents.
International Convention and Exhibition Center Shelter Hospital
Urumqi, Xinjiang, China
Investigator: Panpan Hao, MD
Contact: 86-18560086593
panda.how@sdu.edu.cn
Panpan Hao, MD
86-18560086593
panda.how@sdu.edu.cn
Panpan Hao, MD, Principal Investigator
Qilu Hospital of Shandong University